Clinical Trial Update: Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis [Phase 1]

View source ↗

Summary

This Phase 1 trial of a combination of ruxolitinib phosphate, tacrolimus, and sirolimus to prevent acute graft-versus-host disease in patients undergoing reduce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia in Remission
• Myelofibrosis
• Prefibrotic Stage Primary Myelofibrosis

Drugs mentioned

• Ruxolitinib phosphate (ruxolitinib phosphate)
• Sirolimus (Sirolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Myeloid Leukemia in Remission, Primary Myelofibrosis | Phase 1 | Status: WITHDRAWN